Blueprint Medicines Reports Third Quarter

 Achieved $54.2 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues, representing 90% growth year-over-year, and $56.6 million in total revenues in the third quarter of 2023 –

-- Approximately 800 patients on AYVAKIT in the U.S. at the end of the third quarter, more than 35% growth in treated patients quarter-over-quarter and driven by ISM --

-- Plan to present data from Part 1 of the HARBOR trial of elenestinib in ISM at ASH 2023 –

https://www.prnewswire.com/news-releases/blueprint-medicines-reports-third-quarter-2023-results-301968191.html